These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33175515)

  • 1. Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.
    Karmakar S; Kostrhunova H; Ctvrtlikova T; Novohradsky V; Gibson D; Brabec V
    J Med Chem; 2020 Nov; 63(22):13861-13877. PubMed ID: 33175515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
    Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
    Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ctc-[Pt(NH
    Li Y; Shi S; Zhang S; Gan Z; Wang X; Zhao X; Zhu Y; Cao M; Wang X; Li W
    Dalton Trans; 2021 Aug; 50(32):11180-11188. PubMed ID: 34338267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Anticancer Pt
    Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
    Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
    Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
    Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the Arsenal of Pt
    Yempala T; Babu T; Karmakar S; Nemirovski A; Ishan M; Gandin V; Gibson D
    Angew Chem Int Ed Engl; 2019 Dec; 58(50):18218-18223. PubMed ID: 31599054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.
    Markova L; Maji M; Kostrhunova H; Novohradsky V; Kasparkova J; Gibson D; Brabec V
    J Med Chem; 2024 Jun; 67(11):9745-9758. PubMed ID: 38819023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
    Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
    Qin X; Fang L; Zhao J; Gou S
    Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
    J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity.
    Spector D; Bubley A; Zharova A; Bykusov V; Skvortsov D; Ipatova D; Erofeev A; Gorelkin P; Vaneev A; Mazur D; Nikitina V; Melnikov M; Pergushov V; Bunin D; Kuzmin V; Kostyukov A; Egorov A; Beloglazkina E; Akasov R; Krasnovskaya O
    ACS Appl Bio Mater; 2024 May; 7(5):3431-3440. PubMed ID: 38697834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
    Song Y; Suntharalingam K; Yeung JS; Royzen M; Lippard SJ
    Bioconjug Chem; 2013 Oct; 24(10):1733-40. PubMed ID: 23957697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z; Hu W; Wang Z; Gou S
    Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-action Pt(IV) anticancer agents; do we understand how they work?
    Gibson D
    J Inorg Biochem; 2019 Feb; 191():77-84. PubMed ID: 30471522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
    Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
    Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D
    J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.